To date, there is evidence of ECP in the treatment of epidermolysis bullosa acquisita and bullous pemphigoid but no evidence for the remaining sub-epidermal bullous diseases, such as pemphigoid gestationis, mucous membrane pemphigoid, linear IgA bullous dermatosis, and anti-p200 pemphigoid. Here, CD79A is linked to autoimmune bullous skin disease.